A Review on Unveiling the Impact of First –Line Anti Tubercular Drugs in Tuberculosis Management

Tuberculosis (TB) remains a major global health concern, causing significant morbidity and mortality worldwide. The major aim on this compressive review is to provides an overview of TB, which focused on its epidemiology, etiology, diagnostic methods, and clinical manifestations. This article also described the treatment protocols of 1^st line drug emphasizing their effectiveness, mechanisms of action, and challenges in administration. Standard treatment regimens for TB typically involve a combination of antibiotics, with first-line drugs. Directly observed therapy (DOT) is recommended to ensure treatment adherence and reduce the risk of drug resistance. Despite effective treatment options, challenges such as drug resistance, co-infection with HIV, and inadequate healthcare infrastructure in resource-limited settings continue to pose obstacles to TB control. The primary treatment approach for TB involves a regimen of first-line drugs, which are crucial for effective management and control of the disease. The cornerstone of first-line TB treatment includes medications such as isoniazid, rifampicin, ethambutol, and pyrazinamide, which work synergistically to target different stages of this diseases. Understanding the pharmacological properties and potential side effects of these drugs is essential for optimizing treatment outcomes and minimizing resistance development. These reviews current guidelines and strategies for the administration and monitoring of first-line TB drugs, highlighting the importance of patient adherence to ensure successful treatment. Additionally, it discusses ongoing research efforts aimed at improving drug efficacy, reducing treatment duration, and addressing emerging drug resistance issues. Effective management of TB with first-line drugs remains critical in achieving global TB control targets and improving public health outcomes worldwide.